New hope to stop aggressive esophageal Cancer's return

This study tested if adding an immunotherapy drug (pembrolizumab) after standard surgery and chemoradiation could help prevent esophageal cancer from returning in patients at high risk of recurrence. It involved 26 patients in Taiwan who had already undergone initial treatment but still had features suggesting the cancer was likely to come back. The main goal was to see if this extra treatment improved the one-year survival rate without the cancer returning.